Comparison · NCT02787044-sae
High Dose Influenza Vaccine vs Standard Dose Influenza Vaccine: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. High Dose Influenza Vaccine vs Standard Dose Influenza Vaccine: serious adverse events. Trial comparisons, record NCT02787044-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02787044-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.000767 | 0.00021 | 0.00279 | wilson | |
| Risk in group 2 | 0.00154 | 0.000598 | 0.00394 | wilson | |
| Risk difference, group 1 minus group 2 | -0.000769 | -0.00324 | 0.00146 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.5 | 0.0916 | 2.73 | log | |
| Odds ratio, group 1 over group 2 | 0.499 | 0.0914 | 2.73 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on High Dose Influenza Vaccine than on Standard Dose Influenza Vaccine | 1,300 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | High Dose Influenza Vaccine | High Dose Influenza Vaccine~High Dose Trivalent Influenza Vaccine: High Dose Trivalent Influenza Vaccine | 2 | 2,606 | EG000 |
| Group 2 | Standard Dose Influenza Vaccine | Standard Dose Influenza Vaccine~Standard Dose Quadrivalent Influenza Vaccine: Standard Dose Quadrivalent Influenza Vaccine | 4 | 2,604 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 1 week for post-vaccination adverse events; 1-3 years, depending on length of participation for serious adverse events
Source ClinicalTrials.gov
Trial
- Title
- INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
- NCT number
- NCT02787044
- Phases
- PHASE4
- Conditions
- Heart Failure, Myocardial Infarction
- Interventions
- High Dose Trivalent Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine
- Lead sponsor
- Brigham and Women's Hospital
- Results first posted
- 2021-09-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02787044?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02787044-sae